Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.

Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, Hodson A, Coats J, Narat S, Morley N, Dyer MJS, Collins GP.

Haematologica. 2019 Feb;104(2):e68-e71. doi: 10.3324/haematol.2018.198812. Epub 2018 Sep 6. No abstract available.

2.

Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.

Kozaki R, Vogler M, Walter HS, Jayne S, Dinsdale D, Siebert R, Dyer MJS, Yoshizawa T.

Cancers (Basel). 2018 Apr 23;10(4). pii: E127. doi: 10.3390/cancers10040127.

3.

Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.

Vogler M, Walter HS, Dyer MJS.

Br J Haematol. 2017 Aug;178(3):364-379. doi: 10.1111/bjh.14684. Epub 2017 Apr 27. Review.

PMID:
28449207
4.

Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.

Walter HS, Jayne S, Rule SA, Cartron G, Morschhauser F, Macip S, Karlin L, Jones C, Herbaux C, Quittet P, Shah N, Hutchinson CV, Fegan C, Yang Y, Mitra S, Salles G, Dyer MJS.

Blood. 2017 May 18;129(20):2808-2810. doi: 10.1182/blood-2017-02-765115. Epub 2017 Apr 4. No abstract available.

5.

Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12.

Walter HS, Jayne S, Mensah P, Miall FM, Lyttelton M, Dyer MJ.

Blood Cancer J. 2016 Jun 17;6:e435. doi: 10.1038/bcj.2016.42. No abstract available.

6.

New Agents to Treat Chronic Lymphocytic Leukemia.

Walter HS, Salles GA, Dyer MJ.

N Engl J Med. 2016 Jun 2;374(22):2185-6. doi: 10.1056/NEJMc1602674. No abstract available.

PMID:
27248633
7.

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.

Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV, Honda H, Duffy K, Birkett J, Jamieson V, Courtenay-Luck N, Yoshizawa T, Sharpe J, Ohno T, Abe S, Nishimura A, Cartron G, Morschhauser F, Fegan C, Salles G.

Blood. 2016 Jan 28;127(4):411-9. doi: 10.1182/blood-2015-08-664086. Epub 2015 Nov 5.

8.

Does intravitreal injection of ranibizumab increase the risk for macular hole formation?

Walter HS, Gatzioufas Z, El-Husseiny M, Stavridis E, Seitz B.

Eur J Ophthalmol. 2011 Sep-Oct;21(5):680-1; author reply 1681. doi: 10.5301/EJO.2010.6071. No abstract available.

PMID:
21140364
9.

[Visual diagnosis: Waardenburg syndrome].

Hager T, Walter HS, Seitz B, Käsmann-Kellner B.

Ophthalmologe. 2010 Jul;107(7):660-2. doi: 10.1007/s00347-009-2084-0. German.

PMID:
20024561
10.

[Unclear deterioration of vision after renal transplant].

Hild M, Walter HS, Milioti G, Seitz B.

Ophthalmologe. 2009 Nov;106(11):1024-8. doi: 10.1007/s00347-009-1989-y. German.

PMID:
19585124
11.

Pattern ERG as an early glaucoma indicator in ocular hypertension: a long-term, prospective study.

Bach M, Unsoeld AS, Philippin H, Staubach F, Maier P, Walter HS, Bomer TG, Funk J.

Invest Ophthalmol Vis Sci. 2006 Nov;47(11):4881-7.

PMID:
17065502
12.

[Resource utilisation and cost of amblyopia treatment].

König HH, Walter HS, Barry JC.

Klin Monbl Augenheilkd. 2003 Jul;220(7):486-91. German.

PMID:
12886509

Supplemental Content

Loading ...
Support Center